IMNM - NASDAQ
Immunome, Inc.
$19.81
-4.7%Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
At a Glance
Live SnapshotImmunome, Inc. Management Team
Dr. Clay B. Siegall Ph.D.
Chairman, President & Chief Executive Officer
Compensation
$1,235,350
Mr. Kinney Horn
Chief Business Officer
Compensation
$598,862
Mr. Max Rosett
Chief Financial Officer
Ms. Sandra G. Stoneman Esq., J.D.
Chief Legal Officer, General Counsel & Corporate Secretary
Compensation
$715,350
Dr. Robert J. Lechleider M.D.
Chief Medical Officer
Compensation
$512,488
Dr. Jack Higgins Ph.D.
Chief Scientific Officer
Compensation
$956,342
Dr. Philip Tsai
Chief Technical Officer
Mr. Roee Shahar
Executive Vice President of Commercial
Immunome, Inc. Insider Positioning
During the last 12 months, insiders have purchased $2.10M and sold $11.04M worth of IMNM shares, resulting in $8.94M of net selling activity.
3 Months
32.5K
647.77K
138.1K
2.93M
-2.3M
-$2.29M
3-6 Months
68.5K
1.45M
371.9K
8.08M
-6.6M
-$6.62M
6-9 Months
0
0.00
22.0K
29.70K
-30K
-$30K
9-12 Months
0
0.00
0
0.00
+0
+$0
Top Buyers
Siegall Clay B
Director, Officer: President And Ceo
$1.75M
Tsai Philip
Officer: Chief Technical Officer
$205K
Bienaime Jean Jacques
Director
$147K
Top Sellers
Barchas Isaac
Director
$8.08M
Rosett Max
Officer: Chief Financial Officer
$1.39M
Wagenheim Philip
Director
$1.34M
Higgins Jack
Officer: Chief Scientific Officer
$234K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $8.94M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Weak buy/sell ratio. Selling significantly exceeds buying—monitor for potential fundamental concerns.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
4 insider sellers vs. 3 buyers. More insiders selling than buying suggests cautious or negative sentiment.
Insider Activity Insight
Multiple red flags: Heavy selling, numerous sellers, and continued recent selling create a concerning pattern. Investigate fundamental drivers and consider whether company guidance or industry conditions have deteriorated.
SEC Filings
IMNM - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 24, 2026 | June 09, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 24, 2025 | June 10, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 26, 2024 | June 12, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 20, 2023 | June 07, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 29, 2022 | June 15, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 16, 2021 | May 27, 2021 | 2021 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.